Core products key to solid first half at UCB
This article was originally published in Scrip
Solid growth from core products Cimzia, Vimpat and Neupro helped UCB increase revenue in the first half of the year by 3% to €1.6 billion. The Belgian company reiterated its financial guidance for the full year 2010, saying it expects to achieve total annual revenue of around €3.0 billion.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.